Desire, reignited from within
A cyclic 7-residue melanocortin receptor agonist that acts centrally to drive arousal.
Educational content. This page describes PT-141 (Bremelanotide) for informational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed provider before starting, stopping, or modifying any therapy.
Activates melanocortin-4 receptors (MC4R) in the hypothalamus, increasing dopamine release to enhance sexual motivation at its neurological source.[7]
PT-141 (bremelanotide, marketed as Vyleesi) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). FDA-approved in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, it represents a fundamentally new approach, working through the CNS to enhance desire rather than targeting peripheral blood flow.
Originally developed from melanotan II when researchers discovered unexpected sexual arousal effects, bremelanotide was refined by Palatin Technologies with a clinical program spanning 3,500+ subjects across 43 completed studies. The approval was based on the RECONNECT program: two Phase 3 trials enrolling 1,267 women.
Bremelanotide activates melanocortin-4 receptors (MC4R) in the hypothalamic medial preoptic area, triggering increased dopamine release, directly linked to sexual motivation and desire. Animal models confirm it specifically targets appetitive (desire) rather than consummatory sexual behavior.
In males, additional MC4R-mediated nitric oxide release in the paraventricular nucleus enhances erectile function through descending neural pathways, explaining efficacy in PDE5 inhibitor non-responders.
Following 1.75 mg SC injection, peak plasma levels occur at ~1 hour with 100% bioavailability and ~2.7 hour half-life. The on-demand profile avoids daily dosing.
Desire, reignited from within
Bremelanotide activates MC4R in the hypothalamic medial preoptic area, triggering presynaptic dopamine release that enhances sexual desire and motivation. Unlike PDE5 inhibitors (peripheral vasodilation), it addresses desire at its neurological source. MC1R activation accounts for melanocyte effects; MC4R in the paraventricular nucleus can enhance peripheral erectile mechanisms.
Key studies supporting the therapeutic use of this peptide.
Significantly improved desire scores (effect sizes 0.30-0.42) and reduced sexual distress (effect sizes -0.29 to -0.37) over 24 weeks.
Kingsberg SA, Clayton AH, Portman D, et al. — Obstet Gynecol, 134(5):899-908 (2019) · PubMed
Sustained efficacy over 76 weeks with no new safety signals. Nausea/flushing improved with continued use.
Simon JA, Kingsberg SA, Portman D, et al. — Obstet Gynecol, 134(5):909-917 (2019) · PubMed
33.5% positive response vs 8.5% placebo, with significantly improved intercourse satisfaction.
Safarinejad MR, Hosseini SY — J Urol, 179(3):1066-71 (2008) · PubMed
1.75 mg identified as optimal dose. Significant improvements in satisfying sexual events and FSFI scores.
Clayton AH, Althof SE, Kingsberg SA, et al. — Womens Health (Lond), 12(3):325-37 (2016) · PubMed
Typical protocols used in clinical practice. Always consult a licensed provider for personalized dosing.
Subcutaneous (FDA-approved)
Subcutaneous (FDA-approved): Max 1 dose per 24 hours; max 8 doses per month
Self-administered via Vyleesi autoinjector into abdomen or thigh. Rotate injection sites.
Do not exceed once per 24 hours or 8 doses per month.
Anti-nausea medication recommended for first few doses; nausea improves with subsequent use.
Characterized across 43 studies in 3,500+ subjects. Nausea (40%), flushing (20%), headache (11%) are most common. These are generally mild and improve over time.
Cardiovascular effects modest: 2-3 mmHg systolic BP increase, resolving within 8-12 hours. Contraindicated in uncontrolled hypertension.
Rare hepatotoxicity reported (2 cases across entire development program), resolved after discontinuation.
See how PT-141 (Bremelanotide) compares to peptides with overlapping benefits.
| Peptide | Primary Use | Administration | Cycle Length | Key Differentiator |
|---|---|---|---|---|
| PT-141 (Bremelanotide) | Sexual Health | Injection (as-needed) | Ongoing as-needed | Only FDA-approved on-demand treatment working through CNS melanocortin/dopamine pathways rather than peripheral blood flow |
| Melanotan 2 | Pigmentation & Sexual Function | Injection | 2 weeks (clinical trial protocol) | Non-selective melanocortin agonist producing simultaneous tanning, sexual arousal, and appetite suppression, but with significant safety concerns that prevented regulatory approval |
Current FDA classification and compounding eligibility.
This peptide is an FDA-approved drug available via standard prescription.
FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Available via standard prescription.
FDA approved Vyleesi (bremelanotide 1.75 mg injection) for premenopausal women with acquired HSDD
Last verified April 12, 2026. PepHookup tracks public FDA actions. This is not legal or medical advice.
Looking into PT-141 (Bremelanotide)? Find a provider who knows this peptide and can walk you through your options.
Find a Provider